FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate CancerJaleh Fallah, Paul G. Kluetz, Haley Gittleman et al.|Clinical Cancer Research|2022Cited by 236